BioSante reports beneficial results from Facet II bone up on of Pill-Plus "triple hormone" pronounced contraceptive
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) announced today total results in a Stage II boning up of the Pill-Plus "triple hormone" articulated contraceptive (OC). Results showed an grow in the frequency of propagative pursuit (p< 0.05) and reduced frequency of the old heave-ho of origination of physical occupation by means of sharer (p< 0.05).
“We are glad with the results to engagement in the clinical favour being carried-out in particular Pantarhei Bioscience, our Pill-Plus licensee”
The exploration was a Occasion II double-blind randomized clinical try-out in 82 women comprising a cross-over model of two treatment periods of five months each. The about compared avail oneself of of an OC peerless to the still and all OC with the to boot of an articulated androgen (DHEA). The about was performed at near Dr. Rik van Lunsen and Dr. Ellen Laan from the Be influenced of Sexology of the Unpractical Medical Center in Amsterdam, The Netherlands in closely guarded collaboration with the Professor Herjan Coelingh Bennink and Dr. Yvette Zimmerman from Pantarhei Bioscience in The Netherlands. Earliest results were reported on May 20, 2010 at the 11th Congress of the European Sodality of Contraception in The Hague, The Netherlands. Additional figures hand down be reported upon greatest degree book of the results of the sanctum sanctorum.
Paradoxically, profuse women who point OCs take reduced sensuous solicit, arousabilty and sensual work enough to the effects of estrogen and progestogen in stiffness OCs. The Pill-Plus is designed to touch up testosterone levels that are significantly suppressed during OC expend as documented in this Configuration II mug up. A working order known as female progenitive dysfunction (FSD) in word-of-mouth contraceptive users, middle other aptitude benefits, could be improved large adding an androgen, e.g., DHEA or testosterone to the OC regimen.
"We are chuffed with the results to la mode in the clinical sweat being carried-out ;mainly Pantarhei Bioscience, our Pill-Plus licensee," said Stephen M. Simes, BioSante’s president & CEO. "We look nourish to additional clinical results in the Pill-Plus’ expansion program in the next 12 months. These efforts around Pantarhei in women fetching OCs, in furthermore to our Status III LibiGel clinical program in the treatment of FSD in menopausal women, highlight BioSante as a numero uno in women’s animal vigorousness in the Shared States."
The Pill-Plus Combined States patents for the sake of uttered make use of are licensed away BioSante to Pantarhei Bioscience, a Netherlands-based pharmaceutical companionship, since unfolding and marketing in the Allied States. BioSante retains rights to the Pill-Plus to save transdermal circumstance and marketing.
In annex to this completed work, Pantarhei is preoccupied in respective other Aspect II/III clinical studies of the Pill-Plus. The objectives of the other studies are tons, including investigating the basically of restoration of testosterone levels close to voiced DHEA on the pharmacokinetics of vocal contraceptives and the effects of adding DHEA to word-of-mouth contraceptive treatment on progenitive affair and other measures including frame of mind, muscle come together and tubbiness and bone parameters.
SOURCE BioSante Pharmaceuticals, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
